Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758577 | 0.84 | HTR1A (0.40) | HTR1ASLC6A4 | |
| SCHEMBL7513834 | 0.84 | HTR1A (0.40) | HTR1ASLC6A4 | |
| SCHEMBL5758345 | 0.84 | HTR1A (0.40) | HTR1ASLC6A4 | |
| SCHEMBL5758581 | 0.84 | HTR1A (0.40) | HTR1ASLC6A4 | |
| SCHEMBL5758789 | 0.79 | HTR2C (0.49) | HTR1AHTR2CMEN1KMT2ASLC6A2 | |
| SCHEMBL5758221 | 0.74 | HTR2C (0.46) | HTR1AHTR2CGABRA1GABRG2GABRB3 | |
| Hydrochloric Acid SCHEMBL7099912 | 0.73 | HTR2C (0.47) | HTR1AHTR2CGABRA1GABRG2GABRB3 | |
| SCHEMBL5584362 | 0.72 | HTR2C (0.44) | HTR2CGABRA1GABRG2GABRB3CHRM4 | |
| SCHEMBL5546531 | 0.71 | HTR2C (0.48) | HTR2CGABRA1GABRG2GABRB3MEN1 | |
| SCHEMBL5758016 | 0.69 | L3MBTL1 (0.44) | HTR1AHTR2CMEN1KMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | IDO1, TPH1, IDO2 | HTR1A 4/4885HTR2C 13/4885GABRA1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.